In Vitro and in Vivo Efficacy of NBDHEX on Gefitinib-resistant Human Non-small Cell Lung Cancer

Gefitinib, a first-generation EGFR tyrosine kinase inhibitor (EGFR-TKI), is recommended for treatment of non-small cell lung cancer (NSCLC) patients who harbor activating EGFR mutations. However, the tumors of most patients initially sensitive to gefitinib will develop resistance within several mont...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:J Cancer
Main Authors: Sha, Huanhuan, Dong, Shuchen, Yu, Chen, Zou, Renrui, Zhu, Yue, Lu, Ya, Zhang, Junying, Cao, Haixia, Chen, Dan, Wu, Jianzhong, Feng, Jifeng
Format: Artigo
Jezik:Inglês
Izdano: Ivyspring International Publisher 2020
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7646187/
https://ncbi.nlm.nih.gov/pubmed/33193885
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/jca.46461
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki